The Mayo Clinic expert spoke about stem cell transplantation for patients with myeloma and the factors that affect the ability to collect stem cells.
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.
The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma.
The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them.
In a workshop conducted by the FDA and AACR, researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications.
In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them.
Janssen Pharmaceutical Companies submitted a supplemental biologics license application for daratumumab in combination with carfilzomib and dexamethasone to treat patients with relapsed/refractory multiple myeloma.
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
Researchers used next-generation sequencing to analyze the landscape of neoantigens, identifying neoantigen-specific immune cells triggered by immunotherapy.
Though physical activity guidelines are largely based on chronic diseases like cardiovascular disease and diabetes, these data suggest they are important to cancer prevention as well.